ABBI Abraxis Bioscience (MM)

Abraxis BioScience, Inc. (NASDAQ:ABBI), an integrated, global biopharmaceutical company, today announced it will release its 2007 second quarter financial results before the market opens on Thursday, August 9, 2007. The company also said that senior management will host an investor conference call that same day at 8:30 a.m. PT/11:30 a.m. ET to review the company�s financial results. The conference call will be available to interested parties through a live audio webcast at www.abraxisbio.com and www.earnings.com. The call will also be archived and accessible at both sites for six months. About Abraxis BioScience, Inc. Abraxis BioScience, Inc. is an integrated global biopharmaceutical company dedicated to meeting the needs of critically ill patients. The company�develops, manufactures and markets one of the broadest portfolios of�injectable products and leverages revolutionary technology such as its nab� platform to�discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life-threatening diseases. The first FDA approved product to use this nab platform, ABRAXANE�, was launched in 2005 for the treatment of metastatic breast cancer. Abraxis trades on The Nasdaq Global Market under the symbol ABBI. For more information about the company and its products, please visit www.abraxisbio.com.